| Name | Title | Contact Details |
|---|
PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products.
Cahaba Family Medicine Residency is an unopposed, community-based family medicine training program dually accredited by both the ACGME and AOA. Resurrection Family Medicine is now the Cahaba Urban Residency.
Enclara Pharmacia is the combination resulting from the August 2014 acquisition of Hospice Pharmacia by Enclara Health. We believe that this marriage creates the only true solution for hospice mail order pharmacy services and augments an already robust PBM local offering for hospices that want a choice in their pharmacy service model. Andy Horowitz, CEO, continues to lead Enclara Pharmacia. Enclara Pharmacia serves over 500 hospice providers and 84,000 hospice patients per day nationwide. Enclara’s mail order model provides comprehensive pharmacy support, delivering medications directly to hospice patients’ homes, with the backup of local pharmacies to serve their same-day and emergency needs. Comprehensive services include pharmacist consultation 24/7, patient Drug Utilization Review (DUR), Conditions of Participation (CoP) reports, formulary management, account management, and online reporting—all bundled into a predictable per diem reimbursement model. Enclara Pharmacia’s PBM Plus offering provides you with abundant choice and access to our powerful local pharmacy network contracting platform. The service is offered at a fee for service (FFS) price, unbundled, allowing you to choose the level of clinical intervention, if any, your hospice requires, and to “pay as you go” as those resources are utilized. The program gives the control back to you, supporting overall cost containment.
Learn to Live offers online therapy programs for Stress, Depression and Social Anxiety based on the proven principles of Cognitive Behavioral Therapy (CBT).
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.